Skip to content
10-K

Annual Report

ENDRA Life Sciences Inc. NDRA

0001213900-26-037617

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 31, 2026 1.24M sh
Shares Diluted FY 2025 · Dec 31, 2025 787.02K sh
Capex FY 2025 · Dec 31, 2025 $17.28K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$5.18M
Stockholders Equity FY 2025 · Dec 31, 2025 $2.26M
Current Liabilities FY 2025 · Dec 31, 2025 $750.96K
Total Liabilities FY 2025 · Dec 31, 2025 $1.59M
Current Assets FY 2025 · Dec 31, 2025 $967.97K
Total Assets FY 2025 · Dec 31, 2025 $3.85M
Eps Diluted FY 2025 · Dec 31, 2025 −$8.93
Eps Basic FY 2025 · Dec 31, 2025 −$8.93
Eps Basic FY 2025 · Dec 31, 2024 −$56.94
Sga Expense FY 2025 · Dec 31, 2025 $3.72M
Rd Expense FY 2025 · Dec 31, 2025 $1.85M
Net Income FY 2025 · Dec 31, 2025 −$7.03M
Operating Income FY 2025 · Dec 31, 2025 −$5.76M